[HTML][HTML] Recurrent or primary metastatic cervical cancer: current and future treatments
I Ray-Coquard - ESMO open, 2022 - Elsevier
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
[HTML][HTML] Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L Lapaille… - ESMO Open, 2022 - ncbi.nlm.nih.gov
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
[HTML][HTML] Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L Lapaille… - ESMO Open, 2022 - esmoopen.com
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L Lapaille, MD Cuypere… - 2022 - srhr.dspace-express.com
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L LAPAILLE… - ESMO Open, 2022 - orbi.uliege.be
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L Lapaille… - ESMO …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
Recurrent or primary metastatic cervical cancer: current and future treatments.
C Gennigens, G Jerusalem, L Lapaille… - ESMO Open, 2022 - europepmc.org
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
[引用][C] Recurrent or primary metastatic cervical cancer: current and future treatments
C Gennigens, G Jerusalem, L Lapaille, M De Cuypere… - europepmc.org
Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …